These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Myelodysplastic syndromes (MDS). Klimek V Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724 [No Abstract] [Full Text] [Related]
3. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine. Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918 [No Abstract] [Full Text] [Related]
4. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. Liapis K; Papadopoulos V; Vrachiolias G; Galanopoulos AG; Papoutselis M; Papageorgiou SG; Diamantopoulos PT; Pappa V; Viniou NA; Kourakli A; Τsokanas D; Vassilakopoulos TP; Hatzimichael E; Bouronikou E; Ximeri M; Pontikoglou C; Megalakaki A; Zikos P; Panayiotidis P; Dimou M; Karakatsanis S; Papaioannou M; Vardi A; Kontopidou F; Harchalakis N; Adamopoulos I; Symeonidis A; Kotsianidis I Blood Cancer J; 2021 Feb; 11(2):30. PubMed ID: 33574231 [No Abstract] [Full Text] [Related]
5. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3. Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489 [No Abstract] [Full Text] [Related]
6. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Müller-Thomas C; Rudelius M; Rondak IC; Haferlach T; Schanz J; Huberle C; Schmidt B; Blaser R; Kremer M; Peschel C; Germing U; Platzbecker U; Götze K Haematologica; 2014 Oct; 99(10):e179-81. PubMed ID: 24972774 [No Abstract] [Full Text] [Related]
7. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Lamarque M; Raynaud S; Itzykson R; Thepot S; Quesnel B; Dreyfus F; Rauzy OB; Turlure P; Vey N; Recher C; Dartigeas C; Legros L; Delaunay J; Visanica S; Stamatoullas A; Fenaux P; Adès L Blood; 2012 Dec; 120(25):5084-5. PubMed ID: 23243156 [No Abstract] [Full Text] [Related]
13. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience. Kantarjian HM J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118 [No Abstract] [Full Text] [Related]
14. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply. Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826 [No Abstract] [Full Text] [Related]
15. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine. Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844 [TBL] [Abstract][Full Text] [Related]
16. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879 [No Abstract] [Full Text] [Related]
17. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Prebet T; Fenaux P; Vey N; Haematologica; 2016 Oct; 101(10):e427-e428. PubMed ID: 27694503 [No Abstract] [Full Text] [Related]
18. Azacitine (vidaza) for myelodysplastic syndrome. Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015 [TBL] [Abstract][Full Text] [Related]
19. [Hypomethylating agents for the treatment of myelodysplastic syndromes]. Itzykson R; Fenaux P Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M Leukemia; 2015 Dec; 29(12):2449-51. PubMed ID: 26369829 [No Abstract] [Full Text] [Related] [Next] [New Search]